Dr. Moez Ben Ali is an internationally renowned oncologist and medical researcher specializing in cancer drug development and clinical research. He is currently Senior Medical Director at Fortrea, a global clinical research organization.
Education and Career
Dr. Ben Ali obtained his medical degree with a specialization in oncology, complemented by a PhD in molecular biology focusing on cancer drug development. With over 22 years of professional experience, including 17 years in the pharmaceutical industry, he has held key positions at companies such as Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb, Swedish Orphan Biovitrum (SOBI) and Novartis Oncology across Europe.
Scientific Contributions
As a medical affairs and clinical development strategist, Dr. Ben Ali has led activities throughout the drug development lifecycle, resulting in the registration and launch of 11 drugs with the European Medicines Agency (EMA), nine of which have become standards of care.
Community Engagements
Dr. Ben Ali is a member of several cooperative groups, including the European LeukemiaNet (ELN), the European Organization for Research and Treatment of Cancer (EORTC), and the European Bone Marrow Transplant Group (EBMT). He is also the head of the Oncologists Without Borders organization, demonstrating his commitment to improving cancer care globally.
Conferences and Presentations
Dr. Ben Ali regularly shares his expertise at international conferences. For example, he hosted a conference on « Precision Medicine and Artificial Intelligence » at Pristina University in Tunisia, where he discussed advances in personalized cancer treatment.
Publications
Among his academic contributions, Dr. Ben Ali is the author of the book « Dimerization of the genomic RNA of the avian leukosis virus », which explores the molecular mechanisms related to oncogenic viruses.
Dr. Moez Ben Ali continues to actively contribute to oncology research and the development of innovative therapies, strengthening the links between clinical research and therapeutic applications to improve cancer patient care.